← Back to the catalogue
Lipoproteins and apolipoproteins
PCSK9
Protein that regulates the degradation of the hepatic LDL receptor; its pharmacological inhibition lowers circulating LDL cholesterol.
Application contexts
- Cardiometabolic health
Matrices
- Serum or plasma
Related techniques
- ELISA and immunoassay
Related publications
- An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients. 2019 · Expert opinion on therapeutic targets · 53 citations
- Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders. 2016 · Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis · 45 citations
- Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. 2016 · Cardiovascular diabetology · 38 citations
Show 3 more Show less
- Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children. 2018 · Journal of clinical lipidology · 24 citations
- PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk. 2023 · International journal of molecular sciences · 13 citations
- A case of hypocholesterolemia under study. 2023 · Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis
Related news
- Menopause and cardiovascular health: looking beyond traditional risk factors 20 October 2026 · Panel: Immunoassay and clinical chemistry
- Gut microbiota and metabolism associated with CAR-T therapy response in multiple myeloma 04 November 2025 · Panel: Immunoassay and clinical chemistry
Related projects
There are no projects linked to this biomarker yet.